US Government cuts to mRNA vaccine research could set technological advances, reduce access to therapies, and raise their ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

In an HHS video released yesterday on Fox News, Kennedy said that after consulting with experts from the National Institutes ...

Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV.

During the first RSV season in which a maternal vaccine and a monoclonal antibody for infants were available, 72% of infants were immunized, this study found. Disparities in access to immunization ...

WEDNESDAY, July 30, 2025 (HealthDay News) -- Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.